Overview

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy. As well, the study will determine the response rate to KW-2449.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Pharma, Inc.